대원제약 파도프라잔, 위식도역류질환 임상 3상 목표 달성…품목허가 신청 예정

Resumen del corpus

Daewon Pharmaceutical announced that its drug 'Padoprazan' has met its goals in Phase 3 clinical trials for gastroesophageal reflux disease. The trials, involving 328 patients, demonstrated that Padoprazan showed no significant loss in efficacy compared to the existing treatment, Esomeprazole, and exhibited a favorable safety profile with no serious adverse events. The company plans to submit the final results to the Ministry of Food and Drug Safety and apply for product approval.